Sanofi Obtains EU Panel Recommendation for MS Tablet Aubagio

Sanofi won backing from a European advisory panel for its first multiple sclerosis therapy, the tablet Aubagio, a step forward in the French drugmaker’s plan to grab a slice of the $14 billion MS business.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.